Human RCT
Mensch
Rosenstock J. et al. 2021
Reduction in HbA1c versus placebo and versus semaglutide observed in randomised trials
What does NOT follow: Effect size varies by study dose and concomitant therapy.
Peptide entry · Metabolic
Tirzepatide
LY3298176 · Mounjaro · Zepbound
Highest evidence
Human RCT
Studies recorded
4· 4 in humans
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound).
Researched for
Glycaemic control in type 2 diabetesWeight reduction in obesityCardiovascular outcomesSteatotic liver disease
Official status
US: Prescription
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). Prescription-only.
Overview
What is it?
Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound).
How is it meant to work? →
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled …
What do studies show? →
Human RCTReduction in HbA1c versus placebo and versus semaglutide observed in randomised trials
What do users report? →
On drugs.com, tirzepatide (Mounjaro; as of June 2026) holds an average user rating of 8.4 out of 10 across roughly 1,942 reviews — 77% positive, 6% negative. The most-named theme is gastrointestinal effects (nausea, burping / 'sulfur burps', constipation or diarrhea), described as early and transient in most accounts.⚠ anecdotal – not scientific evidence
01
Mechanism of action
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human RCT
Mensch
Jastreboff AM. et al. 2022
Weight loss over 72 weeks in the obesity-without-diabetes study population
What does NOT follow: Long-term data beyond 2 years are limited; rebound after discontinuation has been observed.
Human trial
Mensch
Reduction in liver fat (MRI-PDFF) reported in patients with non-alcoholic steatohepatitis
What does NOT follow: Phase-2 data; histological endpoints pending.
Human RCT
Mensch
Rosenstock J. et al. 2021
Gastrointestinal adverse events (nausea, vomiting, diarrhoea) are the most commonly documented events in the registration trials
What does NOT follow: Frequency increases with dose; often transient during the titration phase.
04
Where studies disagree
Open question
Does the substantial weight loss come with problematic loss of muscle mass?
POSITION A
A substantial share of weight loss is fat-free (muscle) mass; critics warn of sarcopenia risk, especially in older people.
POSITION B
Loss of fat-free mass accompanies any weight reduction; the proportion resembles that of diet or bariatric surgery, and fat mass falls disproportionately.
CURRENT STATE · Whether the muscle loss is clinically harmful (function, falls) is unresolved; trials combining it with exercise or muscle-preserving agents are ongoing.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 116 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Start time: t₀ = 0.0d
Repeat interval: off (single dose)
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In all SURPASS and SURMOUNT registration trials administered subcutaneously once weekly (abdomen, thigh or upper arm).
06b
Amounts reported in sources
Which amounts were reported in which source — ordered by context (approval, trial, animal model, secondary literature, community).
06c
Storage & stability
What prescribing information and stability literature report about storing the substance — descriptive, not a mixing or usage guide.
Reconstituted · storage
Unopened: 2–8 °C, protected from light; do not freeze.
Reconstituted · shelf life
Limited storage at room temperature (below 30 °C) is permitted per the label for the period stated in the label.
What the stability literature describes
- •Freezing damages the drug; the label describes frozen pens as no longer usable.
- •Keep protected from light.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Nausea
Most frequent adverse event in the SURPASS and SURMOUNT trials; mostly dose-dependent and pronounced in the titration phase. From aggregated trial data — not an individual prediction.
häufig in Titrationsphase
Human RCT
Pancreatitis (rare)
Class effect of GLP-1 RAs. FDA boxed warning concerns thyroid C-cell tumours — observed in rat studies, not confirmed in humans.
selten
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
CautionOral hormonal contraceptivesHuman trial
The label warns that oral contraceptives may be less effective after start and after each dose increase (delayed gastric emptying); the label advises a non-oral method or a barrier method for 4 weeks.
Context: Risk reporting from the label, not a combination guide.
CautionInsulin / sulfonylureasHuman RCT
Increased risk of hypoglycaemia when combined.
Context: Risk reporting from the label.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Thyroid C-cell carcinoma (boxed warning)
The FDA label contains a boxed warning based on tumours in rat studies. Clinical relevance in humans is not confirmed. Personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
FDAU.S. Food and Drug Administration
2023-11-08Press release on Zepbound approval for chronic weight management, November 2023.
Obesity and overweight are serious conditions that can be associated with some of the leading causes of death.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In metabolic and weight-loss communities tirzepatide is often described as more appetite-suppressing and more weight-effective than semaglutide.
very frequent comparison in discussions
Not supported by studies: Subjective cross-comparisons between different individual experiences are not a controlled study. A robust head-to-head exists only for the diabetes context (SURPASS-2); individual response and accompanying measures vary widely.
In US discussions, supply shortages and 'compounded' (pharmacy-mixed) versions are a recurring topic.
periodically dominant US topic
Not supported by studies: Compounded or grey-market products are not the approved finished medicine; identity, purity and content are not subject to regulatory control.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Cofactors
Documented for this class
Protein · Resistance training (muscle preservation)
Open cofactors guide →⚠ Anecdotal (no evidence)
Electrolytes, magnesium & fibre · Vitamin B12 & micronutrients
Open cofactors guide →These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
14
Study register
Human RCTRandomised controlled trialn = 478
Rosenstock J. et al. · 2021
Tirzepatide versus placebo as monotherapy in type 2 diabetes (SURPASS-1)
Concrete results
HbA1c reduction (highest dose arm)
−2.07%
vs Placebo · 40 Wochen
Findings:Significant HbA1c reduction was reported in the treatment arm versus placebo.
Human RCTRandomised controlled trialn = 2539
Jastreboff AM. et al. · 2022
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Concrete results
Mean weight reduction (highest dose arm)
−20.9%
vs Placebo · 72 Wochen
Findings:Substantial weight reduction versus placebo was reported in the treatment arm.
Human RCTRandomised controlled trialn = 1879
Frías JP. et al. · 2021
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
Concrete results
HbA1c difference
−0.45 percentage points
vs Semaglutid 1 mg · 40 Wochen
Human RCTRandomised controlled trial
Garvey WT, et al. · 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
SampleAdults with obesity/overweight AND type 2 diabetes; NCT04657003.
EndpointPercentage change in body weight at 72 weeks.
MethodOnce-weekly subcutaneous dosing (10 or 15 mg) vs. placebo over 72 weeks, with titration.
Concrete results
Mean weight loss (15 mg)
−15,7%
vs −3,3% Placebo · 72 Wochen
Findings:Mean weight loss 13.4% (10 mg) and 15.7% (15 mg) vs. 3.3% on placebo; 79–83% reached ≥5% weight loss vs. 32%.
Limitations:Even with diabetes, weight loss is usually somewhat lower than in people without diabetes; GI effects were the most common adverse events.
15
Sources & method
Reviewed by
editor-placeholder
Last reviewed
2026-05-22
Get new studies on Tirzepatide
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy